ArticleACS nano2011
Aptamer-modified nanodrug delivery systems.
Article in ACS nano, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 51 citations in OpenAlex.
- Shared mechanisms of musculoskeletal dysfunction in type 2 diabetes mellitus: Insights into future therapeutic directions (Review).International journal of molecular medicine · 2026Review
- Adipose tissue-targeted drug delivery for treating obesity: current opportunities and challenges.Drug delivery · 2025Review
- Aptamin C enhances anti-cancer activity NK cells through the activation of STAT3: a comparative study with vitamin C.Anatomy & cell biology · 2024Article
- Review
- Aptamers Enhance Oncolytic Viruses' Antitumor Efficacy.Pharmaceutics · 2022Review
- Aptamer Nanomaterials for Ovarian Cancer Target Theranostics.Frontiers in bioengineering and biotechnology · 2022Review
- Biostable Double-Strand Circular Aptamers Conjugated Onto Dendrimers for Specific Capture and Inhibition of Circulating Leukemia Cells.OncoTargets and therapy · 2020Article
- Simultaneous monitoring of the drug release and antitumor effect of a novel drug delivery system-MWCNTs/DOX/TC.Drug delivery · 2017Article
- A Modular Vaccine Development Platform Based on Sortase-Mediated Site-Specific Tagging of Antigens onto Virus-Like Particles.Scientific reports · 2016Article
- Carbon nanotubes part I: preparation of a novel and versatile drug-delivery vehicle.Expert opinion on drug delivery · 2015Review
- Retro-inverso carbohydrate mimetic peptides with annexin1-binding selectivity, are stable in vivo, and target tumor vasculature.PloS one · 2013Article
- Assembly of aptamer switch probes and photosensitizer on gold nanorods for targeted photothermal and photodynamic cancer therapy.ACS nano · 2012Article
- "OA02" peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo.Cancer research · 2012Article
- Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.Chemical Society reviews · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Aptamers can bind a wide range of biomedically relevant proteins with affinities and specificities that have therapeutic utility. Although aptamers are susceptible to nuclease-mediated degradation and cannot easily cross biological barriers, specific aptamer modification can feasibly solve these problems. To address these obstacles, Lau et al. developed a general strategy for generating natural packaging and transport vehicles for targeting agents, such as aptamers and their small-molecule ligands, by using virus-like particles (VLPs) assembled from the recombinant expression of the bacteriophage Qβ coat protein. Since RNA and DNA molecules are susceptible to nuclease-mediated degradation, it is important that Qβ VLPs protect their encapsulated aptamers from nuclease-mediated degradation and enhance their permeability. Moreover, if self-assembled using natural proteins, VLPs can guarantee the biocompatibility and biodegradability of modified aptamers in therapeutic applications. Therefore, this Perspective explores the outlook for such aptamer modification strategies for nanodrug preparation and delivery applications and the challenges that lie ahead.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.